Listen

Press releases

Receive e-mail alerts

Internal link ProQR Announces Year End 2025 Operating and Financial Results
March 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
March 03, 2026 at 09:30 PM UTC
Internal link ProQR Announces Planned Changes to Board Composition
February 09, 2026 at 01:00 PM UTC
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
January 08, 2026 at 01:00 PM UTC
Internal link ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
December 11, 2024 at 12:00 PM UTC
Internal link ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
December 10, 2024 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
December 05, 2024 at 01:00 PM UTC
Internal link ProQR Announces Third Quarter 2024 Operating and Financial Results
November 07, 2024 at 12:00 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
October 25, 2024 at 08:45 PM UTC
Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
October 23, 2024 at 02:15 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 22, 2024 at 08:01 PM UTC
Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
October 07, 2024 at 12:00 PM UTC
Internal link ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
September 10, 2024 at 08:30 PM UTC
Internal link ProQR Announces Second Quarter 2024 Operating and Financial Results
August 08, 2024 at 11:00 AM UTC
Internal link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
June 18, 2024 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2024 Operating and Financial Results
May 09, 2024 at 11:00 AM UTC
Internal link ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
May 08, 2024 at 12:00 PM UTC
Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
April 23, 2024 at 11:00 AM UTC
Internal link ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
April 22, 2024 at 08:31 PM UTC
Internal link ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024 at 11:00 AM UTC
Internal link ProQR Announces Year End 2023 Operating and Financial Results
March 13, 2024 at 11:00 AM UTC
Internal link ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
February 15, 2024 at 12:00 PM UTC
Internal link ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
January 19, 2024 at 12:00 PM UTC
Internal link ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
January 05, 2024 at 12:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index
December 24, 2018 at 12:00 PM UTC

Press releases

Internal link ProQR Announces Year End 2025 Operating and Financial Results

Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Internal link ProQR Announces Planned Changes to Board Composition

Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Internal link ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

Internal link ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Internal link ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

Internal link ProQR Announces Third Quarter 2024 Operating and Financial Results

Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Internal link ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Internal link ProQR Announces Second Quarter 2024 Operating and Financial Results

Internal link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit

Internal link ProQR Announces First Quarter 2024 Operating and Financial Results

Internal link ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Internal link ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Internal link ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Internal link ProQR Announces Year End 2023 Operating and Financial Results

Internal link ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing

Internal link ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Internal link ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index